Ursula Ehmer

机构：German Cancer Research Center, TUM Klinikum, University Medical Center, Deutsches Konsortium für Translationale Krebsforschung, Technical University of Munich · ORCID：0000-0002-0441-1953

发表论文 156 篇 · 总被引 2840 次 · h-index 29

代表论文

• Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort (2024 · Hepatology Communications · 被引 14)
• Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab (2024 · JHEP Reports · 被引 11)
• PARP-1 selectively impairs KRAS -driven phenotypic and molecular features in intrahepatic cholangiocarcinoma (2024 · Gut · 被引 11)
• Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort (2025 · Alimentary Pharmacology & Therapeutics · 被引 8)
• Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer (2025 · Gut · 被引 7)
• Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study (2025 · Cancers · 被引 7)